SciSparc subsidiary NeuroThera Labs validates quantum sampling workflow for clinical trials analytics platform

• SciSparc unit NeuroThera Labs completed internal validation of a proprietary quantum sampling workflow for clinical trials data analytics.
• Workflow was developed on a hybrid quantum-classical computing platform operated by an unnamed S&P 500 company.
• NeuroThera said the approach converts continuous datasets into quantum-operable representations to support Quantum Markov Chain Monte Carlo methods.
• Platform development runs through CliniQuantum, a quantum analytics initiative in which NeuroThera holds 54.01%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290832PRIMZONEFULLFEED9800154) on July 29, 2026, and is solely responsible for the information contained therein.